Medical Imaging

Physicians utilize medical imaging to see inside the body to diagnose and treat patients. This includes computed tomography (CT), magnetic resonance imaging (MRI), X-ray, ultrasound, fluoroscopy, angiography,  and the nuclear imaging modalities of PET and SPECT. 

Lantheus Holdings announces filing of registration statement for proposed initial public offering

Lantheus Holdings, parent company to Lantheus Medical Imaging, a global leader in developing, manufacturing, selling and distributing innovative diagnostic imaging agents, announced today that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to a proposed initial public offering of its common stock. Lantheus Holdings intends to apply to list its common stock on the NASDAQ Global under the ticker symbol "LNTH." The number of shares to be offered and the price range of the proposed offering have not yet been determined. Lantheus Holdings expects to use the net proceeds of the offering to repay indebtedness of LMI and for working capital and general corporate purposes.

Anti-amyloid therapy being developed to combat Alzheimer’s memory loss

An investigational amyloid antibody treatment called solanezumab is being evaluated by Northwestern University School of Medicine and Rush University Medical Center in Chicago for its efficacy in slowing memory loss caused by Alzheimer's disease.

Thumbnail

Diversified PET/MR differentiates more breast lesions

Using a multiparametric approach, PET/MR imaging with F-18 FDG, dynamic contrast-enhanced MRI, diffusion-weighted imaging and 3-D proton MR spectroscopic imaging is superior for telling apart different kinds of breast tumors, according to a study published online June 24 in Clinical Cancer Research.

IBA to develop, distribute PSMA PET/CT agent for ImaginAb

ImaginAb announced earlier this month that IBA Molecular will be taking on radiochemistry, manufacturing and distribution of the diagnostic immunoPET agent for prostate cancer, Zr-89 Df-IAB2M, as U.S. clinical trials roll out.

Peritumoral contrast enhancement helps diagnose high-grade soft-tissue sarcomas

The presence of peritumoral contrast enhancement is a MRI feature that may be solely used to diagnose high-grade soft-tissue sarcomas (STS), according to a study published in the July issue of Radiology.

Thumbnail

Investigating increased functional connectivity in multiple sclerosis

Increased functional connectivity (FC) is unable to compensate for tissue damage and prevent cognitive dysfunction in patients with multiple sclerosis, according to a study published in the June issue of Radiology.

More government support is needed as regenerative medicine market grows

Regenerative medicine is generating growing interest in terms of research and market investment, according to a data analysis announced June 18 by Frost & Sullivan.

Thumbnail

Chronic REM sleep disorder may lead to neurodegenerative wake-up call

REM behavior disorder (RBD) is highly correlated with the development and progression of neurodegenerative disease including Parkinson’s, according to a brain study presented during the recent Society of Nuclear Medicine and Molecular Imaging’s 2014 Annual Meeting.

Around the web

CCTA is being utilized more and more for the diagnosis and management of suspected coronary artery disease. An international group of specialists shared their perspective on this ongoing trend.

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.